SMaRT correction

Gene therapists have developed a RNA-mediated technique for correcting gene defects that cause cystic fibrosis.

Jonathan Weitzman(jonathanweitzman@hotmail.com)

Jan 8, 2002 | 1 min read

A technique called SMaRT (spliceosome-mediated RNA Trans-splicing) has been developed to generate functionally corrected mRNA transcripts and proteins in patients with genetic diseases. In the January issue of Nature Biotechnology, Liu et al. describe the use of SMaRT technology to correct endogenous ΔF508 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (NatureBiotechnol 2002, 20:47-52).

They constructed recombinant adenoviral vectors containing CFTR exons 10-24 and a trans-splicing domain. These could partially restore CFTR chloride ion conductance in ΔF508 airway epithelial cells in vitro. The SMaRT vectors resulted in the expression of corrected CFTR mRNA and protein. Liu et al. also demonstrated functional correction in vivo using a human bronchial xenograft model. These results show the potential feasibility of using SMaRT technology to correct, rather than replace, defective genes.

Interested in reading more?

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Already a member?

Interested in reading more?

Become a Member of